Terminator: Stem cell cure to destroy liver fibrosis

2016 ◽  
Author(s):  
Biplab Das
Keyword(s):  
Stem Cell ◽  
Liver Fibrosis

scholarly journals Suppression of Carbon Tetrachloride-Induced Liver Fibrosis by Transplantation of a Clonal Mesenchymal Stem Cell Line Derived from Rat Bone Marrow

2009 ◽  
Vol 18 (1) ◽  
pp. 89-100 ◽  
Author(s):  
Marhaen Hardjo ◽  
Masahiro Miyazaki ◽  
Masakiyo Sakaguchi ◽  
Takuro Masaka ◽  
Sukaeni Ibrahim ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Carbon Tetrachloride ◽  
Liver Fibrosis ◽  
Mesenchymal Stem Cell ◽  
Cell Line ◽  
Stem Cell Line ◽  
Rat Bone

scholarly journals Refractory ascites with liver fibrosis developed in late phase allogeneic hematopoietic stem cell transplantation: report of three patients

2016 ◽  
Vol 8 (2) ◽  
Author(s):  
Hiroki Hosoi ◽  
Kenji Warigaya ◽  
Shogo Murata ◽  
Toshiki Mushino ◽  
Kodai Kuriyama ◽  
...  
Keyword(s):  
Stem Cell ◽  
Liver Fibrosis ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Late Phase ◽  
Refractory Ascites ◽  
Hematopoietic Stem ◽  
Hepatic Atrophy

We report cases of three patients of refractory ascites without other fluid retention that occurred around five months after allogeneic hematopoietic stem cell transplantation (allo- HSCT). All three patients expired and postmortem examinations revealed unexpected liver fibrosis lacking histological evidences of graft-<em>versus</em>-host-disease (GVHD). The three patients showed normal hepatic function and size before transplantation. During their clinical courses, serum biochemistry test showed no elevation of hepatic enzymes and bilirubin; however, imaging studies demonstrated hepatic atrophy at the onset of ascites. One of the liver specimens showed bile obstruction, which could be seen in hepatic damage by GVHD. Although ascites resulting from venoocclusive disease in early phase allo-HSCT is well documented, ascites associated with hepatic fibrosis in late phase allo-HCST has not been reported. Further clinico-pathological studies on similar patients should be required to ascertain refractory ascites associated with liver fibrosis after allo-HSCT.

Human adipose stem cell-derived extracellular nanovesicles for treatment of chronic liver fibrosis

2020 ◽  
Vol 320 ◽  
pp. 328-336 ◽  
Author(s):  
Hwa Seung Han ◽  
Hansang Lee ◽  
DongGil You ◽  
Van Quy Nguyen ◽  
Dae-Geun Song ◽  
...  
Keyword(s):  
Stem Cell ◽  
Liver Fibrosis ◽  
Chronic Liver ◽  
Adipose Stem Cell ◽  
Human Adipose Stem Cell

scholarly journals Human Amnion-Derived Mesenchymal Stem Cell Transplantation Ameliorates Liver Fibrosis in Rats

2015 ◽  
Vol 1 (4) ◽  
pp. 1-9 ◽  
Author(s):  
Kimitoshi Kubo ◽  
Shunsuke Ohnishi ◽  
Hidetaka Hosono ◽  
Moto Fukai ◽  
Ayano Kameya ◽  
...  
Keyword(s):  
Stem Cell ◽  
Liver Fibrosis ◽  
Mesenchymal Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Mesenchymal Stem Cell Transplantation ◽  
Human Amnion

scholarly journals Comparative treatment efficiency of adipose and bone marrow derived allogenic mesenchymal stem cell transplantation in mouse models of liver fibrosis

2017 ◽  
Vol 4 (06) ◽  
pp. 1374 ◽  
Author(s):  
Nam Hai Nguyen ◽  
Trinh Van Le ◽  
Huy Quang Do ◽  
Dat Quoc Ngo ◽  
Huy Minh Le ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Adipose Tissue ◽  
Stem Cell ◽  
Liver Fibrosis ◽  
Mesenchymal Stem Cell ◽  
Mouse Model ◽  
Mesenchymal Stem Cell Transplantation ◽  
Liver Histopathology ◽  
Old Mice ◽  
Better Than

Background: The application of mesenchymal stem cell (MSC) therapy in liver fibrosis treatment has been increasingly investigated in recent years. MSCs obtained from a variety of sources (e.g. bone marrow, umbilical cord blood and adipose tissue) have been studied and have achieved remarkable results. In this study, we compared the effects of adipose-derived mesenchymal stem cells (AD-MSC) transplantation with bone marrow-derived mesenchymal stem cell (BM-MSC) transplantation in a mouse model of liver fibrosis, induced by carbon tetrachloride (CCl4). Methods: Eight-week old mice were treated with CCl4 for 11 weeks to induce liver fibrosis then 5x105 cells were transplanted into mice via the tail vein. Results: After 21 days of transplantation, the results showed that the stem cell treated groups ameliorated better than the placebo group. MSC treated groups showed reduced AST and ALT levels, down-regulated expression of extracellular matrix (ECM) genes, and improved liver histopathology. Both sources of MSCs (bone marrow and adipose tissue) were effective in the mouse model of liver fibrosis. Conclusion: Our results also indicated that AD-MSC transplantation in mice accelerated liver regeneration better than BM-MSC transplantation.

Sign in / Sign up

Export Citation Format

Share Document